Actinium Pharmaceuticals (NYSE:ATNM) Stock Rating Lowered by StockNews.com

Actinium Pharmaceuticals (NYSE:ATNM) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday.

A number of other research firms also recently issued reports on ATNM. Maxim Group dropped their target price on shares of Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. HC Wainwright decreased their price objective on shares of Actinium Pharmaceuticals from $50.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Finally, B. Riley downgraded shares of Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the company from $16.00 to $2.00 in a research note on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $11.40.

Actinium Pharmaceuticals Trading Down 2.2 %

ATNM stock traded down $0.04 during midday trading on Wednesday, hitting $1.78. The stock had a trading volume of 353,603 shares, compared to its average volume of 487,733. The business has a 50-day moving average price of $3.85. The company has a market cap of $53.01 million, a price-to-earnings ratio of -1.04 and a beta of 0.14. Actinium Pharmaceuticals has a 12-month low of $1.33 and a 12-month high of $10.24.

Actinium Pharmaceuticals (NYSE:ATNM) last posted its quarterly earnings results on Monday, August 5th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.02. On average, equities research analysts anticipate that Actinium Pharmaceuticals will post -1.38 EPS for the current fiscal year.

Institutional Trading of Actinium Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of Actinium Pharmaceuticals by 6.0% in the 1st quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock worth $11,325,000 after buying an additional 82,113 shares during the last quarter. Sanders Morris Harris LLC bought a new position in Actinium Pharmaceuticals in the first quarter worth about $78,000. Virtu Financial LLC lifted its holdings in Actinium Pharmaceuticals by 319.2% in the first quarter. Virtu Financial LLC now owns 82,029 shares of the company’s stock worth $642,000 after acquiring an additional 62,459 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new position in Actinium Pharmaceuticals in the second quarter valued at approximately $92,000. Finally, Renaissance Technologies LLC bought a new position in shares of Actinium Pharmaceuticals during the second quarter valued at approximately $142,000. Institutional investors and hedge funds own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.